Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: TROP2 methylation and expression in tamoxifen-resistant breast cancer

Fig. 3

5-Aza-dC decreases TACSTD2 DNA promoter methylation and is accompanied by increased mRNA expression in TMX2-28. DNA methylation was analyzed with the Illumina Human Methylation 450 BeadChip. Heatmap represents methylation of CpG sites (average beta-values, scale at right) in TACSTD2 (a), for MCF7-Control, TMX2-28-Control and TMX2-28-5-Aza-dC-treated cell lines. Left: Refgene Group location and MAPINFO number for each CpG site. Bottom: Mean average beta values for the 3 CpGs (orange box) identified as hypermethylated in TMX2-28 compared to MCF7 that have decreased methylation in TMX2-28 after 5-Aza-dC treatment. b Percent DNA methylation of six CpG sites in the promoter region of TACSTD2 determined by pyrosequencing (two of which were CpG sites identified as differentially methylated on the HM450 BeadChip, indicated by orange boxes, CpGs 2 and 6 correspond to MAPINFO numbers 59043280 and 59043255, respectively) for control and 5-Aza- -treated cells. Relative TACSTD2 mRNA expression was quantified by RT-qPCR (c) in control or 48-h or 72-h 5-Aza-treated cells, normalized to beta-actin (n = 3, *p < 0.01, **p < 0.001)

Back to article page